16 reports

  • DISSOLVING MICRONEEDLES - PRODUCT DESCRIPTION

Other revenue reached ™ ## million from ™ ## million in 2017, due to the one-time other revenue in 2017 of ™ ## million for out-licensing of the overthe-counter allergy drug Xyzal® (levoceterizine) in the U. S.

  • Antifungal
  • Clinical Trial
  • Pharmaceutical
  • United States
  • Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS

DRUG HYPERSENSITIVITY REACTIONS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019* PROMINENT DRUGS DRUG HYPERSENSITIVITY REACTIONS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2019*

  • Clinical Trial
  • Drug Development
  • Therapy
  • World
  • Product Initiative

" Although this is still in the experimental stages, we' re delivering on the hope of testing a drug that won' t be for one food allergy but for many, and for other allergic diseases, too. "

  • Allergy Immunotherapy
  • Clinical Trial
  • Medical Biotechnology
  • World
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Development
  • Therapy
  • World
  • Product Initiative

Drug/ Molecule refers to Primary Intervention only. ##.

  • Antifungal
  • Clinical Trial
  • Digestive System Disorder
  • Pharmaceutical
  • World
  • ACT-774312 - DRUG PROFILE

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Clinical Trial
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • Clinical Trial
  • Therapy
  • United States
  • Aldeyra Therapeutics, Inc.
  • ACT-774312 - DRUG PROFILE

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Clinical Trial
  • United States
  • World
  • Product Initiative
  • Clinical Trial profile. 96 Trial Title

Drug/ Molecule refers to Primary Intervention only. ##.

  • Antifungal
  • Clinical Trial
  • Drug Development
  • World
  • Otsuka Pharmaceutical Co., Ltd.

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • Clinical Trial
  • Eye Disease
  • United States
  • Product Initiative

One patient had a fatal SAE, which was not drug related.

  • Antifungal
  • Cancer
  • Clinical Trial
  • United States
  • Product Initiative
  • Clinical Trial profile. 65 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Drug/ Molecule refers to Primary Intervention only. ##.

  • Allergy Drug
  • Antifungal
  • Clinical Trial
  • World
  • Product Initiative

Efficacy was evaluated at Night ## (first drug administration) and after ## weeks of drug administration (Night ##).

  • Clinical Trial
  • Sleep Aid
  • Therapy
  • United States
  • Eisai Co., Ltd.

The FACT ## trial is evaluating the safety and efficacy of Genentech s drugs, Herceptinand Perjeta, and chemotherapy, in early stage breast cancer patients selected with Celcuity s CELx HSF Test.

  • Clinical Trial
  • Diagnostics
  • Monoclonal Antibody
  • Point Of Care Testing
  • Grifols, S.A.

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Clinical Trial
  • Monoclonal Antibody
  • United States
  • SCYNEXIS, Inc.

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Antifungal
  • Clinical Trial
  • United States
  • Product Initiative
  • AstraZeneca PLC